Chiraphat KloypanMatthanaporn SaesongJuthamat SangsuemoonPrawat ChantharitPajaree MongkhonUniversity of PhayaoCharité – Universitätsmedizin BerlinFaculty of Medicine Ramathibodi Hospital, Mahidol UniversityChiang Mai University2022-08-042022-08-042021-11-01European Journal of Clinical Investigation. Vol.51, No.11 (2021)13652362001429722-s2.0-85112686321https://repository.li.mahidol.ac.th/handle/20.500.14594/75989Background: There is still a lack of consensus on the efficacy of convalescent plasma (CP) treatment in COVID-19 patients. We performed a systematic review and meta-analysis to investigate the efficacy of CP vs standard treatment/non-CP on clinical outcomes in COVID-19 patients. Methods: Cochrane Library, PubMed, EMBASE and ClinicalTrials.gov were searched from December 2019 to 16 July 2021, for data from clinical trials and observational studies. The primary outcome was all-cause mortality. Risk estimates were pooled using a random-effect model. Risk of bias was assessed by Cochrane Risk of Bias tool for clinical trials and Newcastle-Ottawa Scale for observational studies. Results: In total, 18 peer-reviewed clinical trials, 3 preprints and 26 observational studies met the inclusion criteria. In the meta-analysis of 18 peer-reviewed trials, CP use had a 31% reduced risk of all-cause mortality compared with standard treatment use (pooled risk ratio [RR] = 0.69, 95% confidence interval [CI]: 0.56-0.86, P =.001, I2 = 50.1%). Based on severity and region, CP treatment significantly reduced risk of all-cause mortality in patients with severe and critical disease and studies conducted in Asia, pooled RR = 0.61, 95% CI: 0.47-0.81, P =.001, I2 = 0.0%; pooled RR = 0.67, 95% CI: 0.49-0.92, P =.013, I2 = 0.0%; and pooled RR = 0.62, 95% CI: 0.48-0.80, P <.001, I2 = 20.3%, respectively. The meta-analysis of observational studies showed the similar results to the clinical trials. Conclusions: Convalescent plasma use was associated with reduced risk of all-cause mortality in severe or critical COVID-19 patients. However, the findings were limited with a moderate degree of heterogeneity. Further studies with well-designed and larger sample size are needed.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.1111/eci.13663